The Latest Analyst Ratings For GeneDx Hldgs
In the latest quarter, 5 analysts provided ratings for GeneDx Hldgs (NASDAQ:WGS), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.8, a high estimate of $35.00, and a low estimate of $11.00. Witnessing a positive shift, the current average has risen by 60.0% from the previous average price target of $13.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of GeneDx Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mark Massaro | BTIG | Raises | Buy | $35.00 | $19.00 |
| Dan Brennan | TD Cowen | Raises | Buy | $24.00 | $14.00 |
| Mark Massaro | BTIG | Raises | Buy | $19.00 | $15.00 |
| Mark Massaro | BTIG | Raises | Buy | $15.00 | $11.00 |
| Matthew Sykes | Goldman Sachs | Raises | Neutral | $11.00 | $6.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to GeneDx Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GeneDx Hldgs compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for GeneDx Hldgs's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
For valuable insights into GeneDx Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on GeneDx Hldgs analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering GeneDx Hldgs: A Closer Look
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.
Key Indicators: GeneDx Hldgs's Financial Health
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, GeneDx Hldgs showcased positive performance, achieving a revenue growth rate of 44.7% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: GeneDx Hldgs's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -32.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): GeneDx Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -9.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): GeneDx Hldgs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.98%, the company may face hurdles in achieving optimal financial returns.
Debt Management: GeneDx Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.57, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.